in vitro Diagnostics.
Ensure and validate at every step of the way.
Immunoassays provide a fast, simple, and cost-effective method of detection with high sensitivity and specificity. They exploit antibodies’ properties to identify pathogens, cancer, and other disease biomarkers, drugs, and other analytes. Without a secure stream of validated monoclonal antibodies (mAbs), IVD developers risk nonspecific binding, batch variability, or loss of supply. At the discovery and development stage, the latter can result in wasted time and resources, or worse, project abandonment, while downstream, during manufacturing, it can lead to substantial costs.
By sequencing the protein of the antibody reagent in parallel to assessing the antibody’s affinity and specificity prior to use, scientists, kit, and reagent manufacturers can eliminate unforeseen surprises. Furthermore, obtaining the protein sequence enables recombinant expression, yielding more consistent batches with predictable biological activity. Next-generation protein sequencing (NGPS) can also help avoid issues with mAbs stemming from cell line drift, gene loss, and gene mutations. Rapid Novor’s NGPS has facilitated the development of reliable kits and immunoreagents securing scientists’ research reproducibility and their trust.
Services for in vitro diagnostic developers.
We support IVD companies and reagent manufacturers in all stages of antibody selection, development, characterization, validation and production. Contact us to discover how we can help with your IVD application.
de novo mAb Sequencing
Safeguard the sequence of high-demand immunoreagents for posterity, and/or IP, or to meet regulatory guidelines.
Explore REmAb
Fast ADA assays
Custom anti-drug antibody (ADA) control reagents assess clinical safety and efficacy in biologics and biosimilars. ADAs derived from the circulating polyclonal antibodies (pAb) can be easily derived by polyclonal antibody sequencing.
Explore REpAb + Expression
Quality Control and Troubleshooting
Routinely certify immunoreagents by confirming the expected sequence for the highest quality and minimal troubleshooting.
Explore MATCHmAb
Application Publications.
Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing
Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.
De Novo Protein Sequencing
Abstract In this on-demand webinar, we briefly cover the fundamentals of protein sequencing, how researchers have benefited from implementing protein [...]
Monoclonal Vs. Polyclonal Antibody Drugs
The transition from polyclonal antibody drugs to a more targeted monoclonal approach was made possible through a series of scientific and technological advancements; the most notable of which is the hybridoma technique developed by Köhler and Milstein, which allowed the generation of pure antibodies at scale.
What are Monoclonal Antibodies?
Monoclonal antibodies (mAbs) are homogenous antibodies that bind to a single epitope on an antigen. Kohler and Milstein generated the first mAbs when they developed hybridoma technology in the 1970s. Because of the specificity, homogeneity and unlimited availability, mAbs are valuable reagents used in a variety of important applications including treatment and diagnosis of diseases
“The protein sequence allowed us to control the antibody, affinity maturation, and do large production. Being able to produce 20mg of Ab is big advantage.”
Talk to Our Scientists.
We Have Sequenced 4000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics